Uromigos-Bladder Cancer
Dr. Meeks discusses expression-based subtypes for defining pathologic response to neoadjuvant ICIs in patients with MIBC.
Sia Daneshmand, MD, reviews 2 studies on the use of erdafitinib for the treatment of NMIBC, including the THOR-2 trial.
The Uromigos are joined by Kala Sridhar, MD, to discuss the PET MUSE study on the impact of PET imaging in MIUC.
Michiel Van der Heijden, MD, PhD, joined The Uromigos to review bladder cancer research from the 2023 ASCO GU Symposium.
Matt Galsky, MD discusses updates for the CheckMate 274 Trial at the 2023 ASCO GU Cancers Symposium with The Uromigos.
Enrique Grande, MD, PhD, Msc, met with The Uromigos at the 2023 ASCO GU Cancers Symposium to discuss the IMvigor130 study.
Andrea Necchi, MD describes the results of the phase 2 KEYNOTE-057 study at the 2023 ASCO GU Cancers Symposium.
Vadim Koshkin, MD, discusses the prevalence of HER2 expression in bladder cancer and the UNITE study for advanced UC.
Petros Grivas, MD, PhD, joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer.
A summary of the prostate and bladder cancer session of the Conversations & Trending Topics in GU Cancers conference.
Sam Chang, MD, MBA, joins The Uromigos to discuss the results of IL-15RαFc superagonist N-803 for papillary NMIBC.
Is cisplatin any different from carboplatin in advanced bladder cancer? The Uromigos debate the topic with Matt Galsky, MD.
Dr. Andrea Necchi describes his recent phase 2 study on the use of neoadjuvant pembrolizumab and nab-paclitaxel for MIBC.
The Uromigos chat with Cora Sternberg on her paper on FGFR inhibition in advanced urothelial cancer.
John Kelly summarizes a recent paper published in JAMA that describes the benefits of robotic surgery versus open cystectomy.
Cora Sternberg, MD, discusses her career that has spanned multiple continents.
Syed Hussain and Sam Funt describe their studies on this topic.
Matt Galsky and Tom Powles take the FDA and EMA approach respectively concerning adjuvant nivolumab for bladder cancer.
Cisplatin-based combination chemotherapy is considered standard of care in mUC, but many patients are deemed ineligible.
Dr. Jonathan Rosenberg describes the results of this positive randomized phase 2 trial.
670 Madison Ave.
Manalapan, NJ 07726